Purpose

The investigators aim is to conduct a randomized clinical trial in an underserved population who are either uninsured or on Medicaid and taking at least one injection of insulin daily. The investigators believe that this study will lead to considerable alleviation of health disparities and provide better care for an underserved population. This will be a pilot study to evaluate the feasibility of such a trial in this population before doing a larger multicenter trial.

Conditions

Eligibility

Eligible Ages
Between 18 Years and 75 Years
Eligible Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Age 18-75 years - Type 2 diabetes mellitus - HbA1C ≥ 7.5% - At least on 1 insulin injection therapy daily - Patients established with primary care clinic or endocrinology clinic or diabetes clinics in the New Orleans and surrounding areas - Patients with Medicaid or free care or uninsured - Patients must be able to speak and understand English and be capable of providing informed consent to participate in the study

Exclusion Criteria

  • Type 1 diabetes mellitus - Currently on CGM or using insulin pump - Advanced renal disease or Estimated Glomerular Filtration Rate (eGFR) <40 - Serious co-morbidities which in the investigator's opinion, will make it challenging for patients to participate - The patient has been diagnosed with end-stage renal disease, is on dialysis, or has had a kidney transplant, Hemoglobinopathies, iron therapy or other condition that interferes with HbA1c measurement - Pregnant

Study Design

Phase
N/A
Study Type
Interventional
Allocation
Randomized
Intervention Model
Crossover Assignment
Primary Purpose
Prevention
Masking
None (Open Label)

Arm Groups

ArmDescriptionAssigned Intervention
Placebo Comparator
Self-Monitoring of Blood Glucose (SMBG)
The study participants will be randomized to the self-monitoring group (control) after a period of two-week run-in and followed for 6 months. They will be given an opportunity to wear the CGM sensor for 3 months at the conclusion of the 6-month follow-up as an optional follow-up.
  • Device: Continuous Glucose Monitoring (CGM)
    Continuous glucose monitors will be placed subcutaneously every 14 days.
Active Comparator
Continuous Glucose Monitoring (CGM)
The study participants will be randomized to the continuous glucose monitoring group (intervention).
  • Device: Continuous Glucose Monitoring (CGM)
    Continuous glucose monitors will be placed subcutaneously every 14 days.

Recruiting Locations

University Medical Center
New Orleans, Louisiana 70112
Contact:
Neha Upadhyay, BDS,MPH
504-988-9803
nupadhyay@tulane.edu

More Details

Status
Recruiting
Sponsor
Tulane University

Study Contact

Neha Upadhyay, BDS,MPH
5049889803
nupadhyay@tulane.edu

Detailed Description

This study is a randomized open label trial with study participants being randomized to either a continuous glucose monitoring group (intervention) or a self-monitoring group (control) after a period of two-week run-in and followed for 6 months. All participants regardless of assignment will be provided diabetes education. Participants randomized to the self-monitoring group will be given an opportunity to wear the CGM sensor for 3 months at the conclusion of the 6-month follow-up as an optional follow-up.

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.